Crohn DiseaseNCT04159597
Expanded Access to Upadacitinib
A study testing Upadacitinib in people with Crohn Disease and Ulcerative Colitis, run by AbbVie.
Trial summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA)
- What is being tested?
- Upadacitinib
- Type of treatment
- Pill or oral medicine
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- There are other suitable treatment options.
- The participant qualifies for ongoing clinical trials.
Trial locations and contacts
No sites are listed yet.
About this study
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis, Rheumatoid Arthritis, Psoriatic Arthritis
- Being tested
- Upadacitinib
- Keywords
- Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme
- Medical subject headings
- Crohn Disease, Colitis, Ulcerative, Dermatitis, Atopic, Arthritis, Rheumatoid, Arthritis, Psoriatic, Axial Spondyloarthritis, Spondylarthritis, Giant Cell Arteritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
UpadacitinibDrug
Also called ABT-494, Rinvoq, C25-267
Upadacitinib will be administered as oral solution.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Crohn DiseaseStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04159597
- Sponsor's protocol ID
- C20-082
- Other IDs
- C25-267
- Status last verified
- Aug 2026
- First submitted
- 7 Nov 2019
- Last updated
- 20 Aug 2026
- Results posted
- No